A study examining the neutrophil-to-lymphocyte ratio associates with nutritional parameters, intratumoral immune profiles, and clinical outcomes of pembrolizumab in head and neck squamous cell carcinoma
Latest Information Update: 26 Jul 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 01 Aug 2024 Results published in the Head and Neck
- 26 Jul 2024 New trial record